Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 7410 participants.

Also called NCT02915198

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 7,410 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02915198
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT02915198. Randomized; quadruple masking; primary purpose treatment. Start 2023-04-03 (actual); primary completion 2029-09-28 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
Acronym
VA-IMPACT
Condition
Prediabetic State
Condition
Atherosclerosis
Condition
Metformin
Intervention (Drug)
Metformin XR
Intervention (Drug)
Placebo
Lead sponsor
VA Office of Research and Development (class: US federal agency)

Record details

Record id
cardio:ct-nct02915198
Content hash
eb744d0bc295b9a6a57f0b3f25cadf73d9ee78435cda961a6f0309860aa62936